Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

Area of Science:

• Hematology
• Oncology
• Epigenetics

Background:

• Peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS) are aggressive and difficult to classify, with poor outcomes.
• Identifying actionable biomarkers is crucial for developing targeted therapies for PTCL-NOS.
• Epigenetic alterations, including histone modifications, are implicated in cancer progression.

Purpose of the Study:

• To investigate the role of histone modification genes in PTCL-NOS.
• To identify potential therapeutic targets and strategies for PTCL-NOS based on epigenetic alterations.
• To evaluate the efficacy of epigenetic drugs, such as chidamide and decitabine, in PTCL-NOS.

Main Methods:

• Screening of core histone methylation (KMT2D, SETD2, KMT2A, KDM6A) and acetylation (EP300, CREBBP) genes for somatic mutations in PTCL-NOS patients.
• Association of mutations with clinical outcomes, including progression-free survival.
• In vitro studies assessing the effects of chidamide and decitabine on lymphoma cell growth.
• Mechanistic studies to elucidate the synergistic effects of chidamide and decitabine.
• In vivo xenograft model studies to evaluate the therapeutic potential of dual treatment.

Main Results:

• Somatic mutations in histone modifier genes were identified in 36.0% of PTCL-NOS patients.
• Histone modifier gene mutations correlated with inferior progression-free survival.
• Mutated PTCL-NOS cells showed increased sensitivity to the histone deacetylase inhibitor chidamide.
• Combination therapy with chidamide and decitabine demonstrated synergistic inhibition of lymphoma cell growth in vitro and tumor growth in vivo.
• Dual treatment modulated the KMT2D/H3K4me axis, enhancing apoptosis.

Conclusions:

• Aberrant histone modification is a key feature in a subset of PTCL-NOS.
• Mutations in histone modifier genes can serve as biomarkers for predicting response to epigenetic therapy.
• Combination epigenetic therapy with chidamide and decitabine offers a promising therapeutic strategy for PTCL-NOS.